Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells

Decollogne, Stéphanie and Joshi, Swapna and Chung, Sylvia A. and Luk, Peter P. and Yeo, Reichelle X. and Nixdorf, Shery and Fedier, André and Heinzelmann-Schwarz, Viola and Hogg, Philip J. and Dilda, Pierre J.. (2015) Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells. Gynecologic Oncology, 138 (2). pp. 363-371.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/61854/

Downloads: Statistics Overview


OBJECTIVE: The purpose of this study was to test PENAO, a promising new organoarsenical that is in phase 1 testing in patients with solid tumours, on a range of ovarian cancer cell lines with different histotypes, and to understand the molecular basis of drug resistance exhibited by the endometrioid ovarian cancer cell line, SKOV-3. METHODS: Proliferation arrest and cell death induced by PENAO in serous (OVCAR-3), endometrioid (SKOV-3, TOV112D), clear cell (TOV21G) and mucinous (EFO27) ovarian cancer cells in culture, and anti-tumour efficacy in a murine model of SKOV-3 and OVCAR-3 tumours, were measured. Cells were analysed for cell cycle arrest, cell death mechanisms, reactive oxygen species production, mitochondrial depolarisation, oxygen consumption and acid production. RESULTS: PENAO demonstrated promising anti-proliferative activity on the most common (serous, endometrioid) as well as on rare (clear cell, mucinous) subtypes of ovarian cancer cell lines. No cross-resistance with platinum-based drugs was evident. Endometrioid SKOV-3 cells were, however, shown to be resistant to PENAO in vitro and in a xenograft mouse model. This resistance was due to an ability to cope with PENAO-induced oxidative stress, notably through heme oxygenase-1 induction, and a shift in metabolism towards glycolysis. The adaptive glycolytic shift in SKOV-3 was targeted using a mTORC1 inhibitor in combination with PENAO. This strategy was successful with the two drugs acting synergistically to inhibit cell proliferation and to induce cell death via apoptosis and autophagy. CONCLUSION: Mitochondria/mTOR dual-targeting therapy may constitute a new approach for the treatment of recurrent/resistant forms of epithelial ovarian cancer.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Gynecological Research (Heinzelmann)
UniBasel Contributors:Heinzelmann, Viola
Item Type:Article, refereed
Article Subtype:Research Article
ISSN:1095-6859 (Electronic) 0090-8258 (Linking)
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:03 Nov 2018 09:02
Deposited On:03 Nov 2018 09:02

Repository Staff Only: item control page